Impact of long-term ticagrelor monotherapy following 1-month dual antiplatelet therapy in patients who underwent complex percutaneous coronary intervention: insights from the Global Leaders trial.

AIMS To evaluate the impact of an experimental strategy [23-month ticagrelor monotherapy following 1-month dual antiplatelet therapy (DAPT)] vs. a reference regimen (12-month aspirin monotherapy following 12-month DAPT) after complex percutaneous coronary intervention (PCI). METHODS AND RESULTS In the present post hoc analysis of the Global Leaders trial, the primary endpoint [composite of all-cause death or new Q-wave myocardial infarction (MI)] at 2 years was assessed in patients with complex PCI, which includes at least one of the following characteristics: multivessel PCI, ≥3 stents implanted, ≥3 lesions treated, bifurcation PCI with ≥2 stents, or total stent length >60 mm. In addition, patient-oriented composite endpoint (POCE) (composite of all-cause death, any stroke, any MI, or any revascularization) and net adverse clinical events (NACE) [composite of POCE or Bleeding Academic Research Consortium (BARC) Type 3 or 5 bleeding] were explored. Among 15 450 patients included in this analysis, 4570 who underwent complex PCI had a higher risk of ischaemic and bleeding events. In patients with complex PCI, the experimental strategy significantly reduced risks of the primary endpoint [hazard ratio (HR): 0.64, 95% confidence interval (CI): 0.48-0.85] and POCE (HR: 0.80, 95% CI: 0.69-0.93), but not in those with non-complex PCI (Pinteraction = 0.015 and 0.017, respectively). The risk of BARC Type 3 or 5 bleeding was comparable (HR: 0.97, 95% CI: 0.67-1.40), resulting in a significant risk reduction in NACE (HR: 0.80, 95% CI: 0.69-0.92; Pinteraction = 0.011). CONCLUSION Ticagrelor monotherapy following 1-month DAPT could provide a net clinical benefit for patients with complex PCI. However, in view of the overall neutral results of the trial, these findings of a post hoc analysis should be considered as hypothesis generating.

[1]  P. Serruys,et al.  Patient-oriented composite endpoints and net adverse clinical events with ticagrelor monotherapy following percutaneous coronary intervention: Insights from the randomized GLOBAL LEADERS trial. , 2019, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[2]  L. Räber,et al.  Validation of High-Risk Features for Stent-Related Ischemic Events as Endorsed by the 2017 DAPT Guidelines. , 2019, JACC. Cardiovascular interventions.

[3]  Volkmar Falk,et al.  2018 ESC/EACTS Guidelines on myocardial revascularization. , 2018, European heart journal.

[4]  G. Giustino,et al.  Optimal duration of dual antiplatelet therapy after PCI: integrating procedural complexity, bleeding risk and the acuteness of clinical presentation , 2018, Expert review of cardiovascular therapy.

[5]  G. Stone,et al.  Impact of percutaneous coronary intervention extent, complexity and platelet reactivity on outcomes after drug-eluting stent implantation. , 2018, International journal of cardiology.

[6]  Deepak L. Bhatt,et al.  Aspirin-free strategies in cardiovascular disease and cardioembolic stroke prevention , 2018, Nature Reviews Cardiology.

[7]  J. Spertus,et al.  Standardized End Point Definitions for Coronary Intervention Trials: The Academic Research Consortium-2 Consensus Document , 2018, European heart journal.

[8]  James E. Tcheng,et al.  2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials , 2018, Circulation.

[9]  Akshay S. Desai,et al.  2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials. , 2018, Journal of the American College of Cardiology.

[10]  J. Massaro,et al.  Lesion Complexity and Outcomes of Extended Dual Antiplatelet Therapy After Percutaneous Coronary Intervention. , 2017, Journal of the American College of Cardiology.

[11]  Lehana Thabane,et al.  An introduction to multiplicity issues in clinical trials: the what, why, when and how. , 2016, International journal of epidemiology.

[12]  C. Held,et al.  Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial , 2016, European heart journal.

[13]  Deepak L. Bhatt,et al.  Efficacy and Safety of Dual Antiplatelet Therapy After Complex PCI. , 2016, Journal of the American College of Cardiology.

[14]  I. Palacios,et al.  Treatment of Higher-Risk Patients With an Indication for Revascularization: Evolution Within the Field of Contemporary Percutaneous Coronary Intervention , 2016, Circulation.

[15]  A. Yeung,et al.  Trial of everolimus-eluting stents or bypass surgery for coronary disease. , 2015, The New England journal of medicine.

[16]  M. Reynolds,et al.  Trends in Coronary Revascularization Procedures Among Medicare Beneficiaries Between 2008 and 2012 , 2015, Circulation.

[17]  R. Wilensky,et al.  Five-year follow-up of patients treated for coronary artery disease in the face of an increasing burden of co-morbidity and disease complexity (from the NHLBI Dynamic Registry). , 2014, The American journal of cardiology.

[18]  K. Alexander,et al.  Nuisance bleeding with prolonged dual antiplatelet therapy after acute myocardial infarction and its impact on health status. , 2013, Journal of the American College of Cardiology.

[19]  Marco Valgimigli,et al.  Standardized Bleeding Definitions for Cardiovascular Clinical Trials: A Consensus Report From the Bleeding Academic Research Consortium , 2011, Circulation.

[20]  P. Serruys,et al.  The impact of patient and lesion complexity on clinical and angiographic outcomes after revascularization with zotarolimus- and everolimus-eluting stents: a substudy of the RESOLUTE All Comers Trial (a randomized comparison of a zotarolimus-eluting stent with an everolimus-eluting stent for percutan , 2011, Journal of the American College of Cardiology.

[21]  Volkmar Falk,et al.  Guidelines on Myocardial Revascularization the Task Force on Myocardial Revascularization of the European Society of Cardiology (esc) and the European Association for Cardio-thoracic Surgery (eacts) Developed with the Special Contribution of the European Association for Percutaneous Cardiovascular I , 2022 .

[22]  P. Serruys,et al.  Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions , 2007, Circulation.